---

---

tags : Cancer    symbols : JNJ   

save search

---

American Lung Association and LUNGevity Foundation Announce $3 Million Research Partnership to Intercept Lung Cancer
Published: 2024-04-09 (Crawled : 11:00) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -4.63% | O: -0.3% H: 0.0% C: 0.0%
partnership lung association million cancer research foundation

---

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
NBTX | News | $5.35 -3.08% -3.18% 43K |

Manufacturing

| -11.8% | O: 3.11% H: 1.19% C: -2.54%
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -8.22% | O: 0.02% H: 0.0% C: 0.0%
lung cancer treatment

---

Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -8.46% | O: -0.28% H: 0.27% C: 0.04%
cancer therapy

---

RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson's ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
Published: 2024-03-18 (Crawled : 12:00) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -8.52% | O: 0.2% H: 0.08% C: -1.14%
rybrevant lung cancer cell care

---

World Cancer Immunotherapy Market Research 2023-2027: Curing Cancer is Generating Enormous New Opportunities - Outcome Potential, Technology Environment, Target Solutions
Published: 2024-03-16 (Crawled : 04:20) - prnewswire.com
BIIB | $192.13 -1.55% -1.57% 1.3M |

Health Technology

| Email alert Add to watchlist
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| Email alert Add to watchlist
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.116 -2.18% 2.3K |

Health Technology

| Email alert Add to watchlist
world cancer research solutions immunotherapy technology market

---

Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer
Published: 2024-03-14 (Crawled : 08:00) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -10.9% | O: -1.04% H: 0.0% C: 0.0%
cancer treat series cell

---

RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| Email alert Add to watchlist
rybrevant fda first lung approved cancer cell treatment therapy

---

Liquid Biopsy Market Set to Reach US$ 10.08 Billion by 2030 with Pioneering Breakthroughs in Cancer Detection and Management
Published: 2024-02-16 (Crawled : 19:00) - prnewswire.com
TMO | News | $547.25 -1.32% -0.02% 1.6M |

Health Technology

| Email alert Add to watchlist
EXAS | $63.21 -1.02% -1.03% 2.5M |

Health Technology

| Email alert Add to watchlist
QGEN | $39.23 -0.23% 0.0% 800K |

Health Technology

| Email alert Add to watchlist
QGEN | $39.23 -0.23% 0.0% 800K |

Health Technology

| Email alert Add to watchlist
LH M | $199.97 -0.97% 0.0% 680K |

Health Services

| Email alert Add to watchlist
ILMN | $118.305 0.52% 0.52% 1.9M |

Health Technology

| Email alert Add to watchlist
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| Email alert Add to watchlist
management reach cancer set market

---

FDA Decisions: First Frontline Pancreatic Cancer Treatment Approved in More t...
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K |

Health Technology

| 2.49% | O: 1.16% H: 1.48% C: 0.89%
PRGO | $30.04 0.27% 0.0% 780K |

Health Technology

| -4.82% | O: 0.67% H: 2.06% C: 1.86%
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -7.36% | O: -0.19% H: 1.6% C: 1.24%
ABT | News | $105.9 -3.03% 0.07% 12M |

Health Technology

| -3.69% | O: 0.41% H: 0.0% C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| 0.99% | O: 1.86% H: 0.0% C: 0.0%
fda first approved cancer pancreatic treatment

---

FDA Decisions: First Frontline Pancreatic Cancer Treatment Approved in More than a Decade
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K |

Health Technology

| 2.49% | O: 1.16% H: 1.48% C: 0.89%
PRGO | $30.04 0.27% 0.0% 780K |

Health Technology

| -4.82% | O: 0.67% H: 2.06% C: 1.86%
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -7.36% | O: -0.19% H: 1.6% C: 1.24%
ABT | News | $105.9 -3.03% 0.07% 12M |

Health Technology

| -3.69% | O: 0.41% H: 0.0% C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| 0.99% | O: 1.86% H: 0.0% C: 0.0%
fda first approved cancer pancreatic treatment

---

Prevention and Treatment of Prostate Cancer: Global Market for Prostate Cancer Screening and Detection is Projected to Grow at a CAGR of 5.8% to Reach $19.8 billion by 2028
Published: 2024-02-09 (Crawled : 15:30) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -7.81% | O: -0.68% H: 0.0% C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| 0.04% | O: 1.11% H: 0.0% C: 0.0%
reach cancer treatment global market

---

Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | News | $9.594 43.47% 2.2K |

Health Technology

| -13.72% | O: -1.53% H: 0.0% C: 0.0%
AZNCF | $135.305 -4.19% 1.1K |

Health Technology

| 1.09% | O: -0.37% H: 0.0% C: 0.0%
NVSEF | News | $93.6375 6.88% 82K |

Health Technology

| -8.98% | O: 0.41% H: 0.0% C: 0.0%
UCBJY | $63.31 -4.38% 9.4K |

Manufacturing

| 37.02% | O: 1.71% H: 1.28% C: 0.94%
ALPMY | News | $9.34 -1.11% 690K |

Manufacturing

| -14.23% | O: 0.28% H: 0.18% C: 0.0%
TAK | $13.15 -0.61% 0.0% 1.6M |

Health Technology

| -7.13% | O: 0.07% H: 0.42% C: 0.07%
NVS | News | $93.08 -0.13% 0.86% 1.2M |

Health Technology

| -10.28% | O: 0.09% H: 0.39% C: -0.36%
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -7.04% | O: 1.47% H: 0.0% C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M |

Health Technology

| 6.49% | O: 0.76% H: 4.31% C: 2.11%
BMY | $47.84 -0.87% -0.02% 12M |

Health Technology

| -2.03% | O: -0.14% H: 0.35% C: -1.12%
ABBV | $164.25 1.05% -0.76% 4M |

Health Technology

| -3.96% | O: 1.48% H: 0.0% C: 0.0%
VRTX | $393.1 -0.27% -0.27% 880K |

Health Technology

| -5.53% | O: 0.15% H: 2.4% C: 0.56%
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| -0.9% | O: 1.33% H: 0.0% C: 0.0%
JAZZ | News | $107.15 -1.61% -1.63% 590K |

Health Technology

| -14.12% | O: -0.02% H: 0.0% C: -1.4%
AZN | $68.53 0.39% 0.39% 3.7M |

Health Technology

| 1.83% | O: -0.4% H: 0.19% C: -0.33%
AMGN | $264.07 -0.59% -0.59% 2.2M |

Health Technology

| -15.55% | O: -0.18% H: 0.0% C: -6.22%
report cancer blood growth market

---

Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU
Published: 2024-01-24 (Crawled : 14:30) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -9.61% | O: -0.32% H: 0.0% C: 0.0%
asco bladder cancer treatment

---

Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
Published: 2024-01-23 (Crawled : 11:01) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -10.61% | O: -1.11% H: 0.0% C: 0.0%
million cancer series therapeutics

---

FDA Decisions: J&J's Bladder Cancer Drug Wins Full Approval
Published: 2024-01-22 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K |

Health Technology

| -8.68% | O: 1.71% H: 0.0% C: -0.15%
PRGO | $30.04 0.27% 0.0% 780K |

Health Technology

| -9.22% | O: 0.36% H: 2.11% C: 1.29%
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -10.08% | O: 0.6% H: 0.0% C: 0.0%
ABT | News | $105.9 -3.03% 0.07% 12M |

Health Technology

| -5.27% | O: 0.88% H: 0.0% C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| -10.01% | O: -0.21% H: 0.0% C: 0.0%
fda drug approval bladder cancer

---

J&J Secures Full FDA Approval for Bladder Cancer Drug Balversa
Published: 2024-01-22 (Crawled : 13:30) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -10.08% | O: 0.6% H: 0.0% C: 0.0%
fda drug approval bladder cancer balversa

---

U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
Published: 2024-01-19 (Crawled : 21:00) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| Email alert Add to watchlist
balversa drug genetic approval food bladder cancer treat grants advanced

---

FDA Decisions: Merck's Keytruda Wins 39th Overall Approval, Third in Cervical Cancer
Published: 2024-01-15 (Crawled : 17:00) - biospace.com/
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.116 -2.18% 2.3K |

Health Technology

| Email alert Add to watchlist
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| Email alert Add to watchlist
PRGO | $30.04 0.27% 0.0% 780K |

Health Technology

| Email alert Add to watchlist
ABT | News | $105.9 -3.03% 0.07% 12M |

Health Technology

| Email alert Add to watchlist
fda cancer keytruda

---

Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-12-21 (Crawled : 13:00) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -7.46% | O: -1.87% H: 0.0% C: 0.0%
rybrevant fda lung drug license approval cancer cell treatment application plus

---

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight
Published: 2023-12-20 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K |

Health Technology

| -3.34% | O: -0.1% H: 0.0% C: 0.0%
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -7.46% | O: -1.87% H: 0.0% C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M |

Health Technology

| 31.67% | O: 0.21% H: 0.63% C: 0.1%
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| -5.45% | O: -0.08% H: 0.0% C: 0.0%
cancer growth study market

---

Gainers vs Losers

56%

44%

Top 10 Gainers

INVO | $1.76 131.58% 56.82% 230M |

Health Technology

SINT | $0.0365 59.39% 37.26% 470M |

Health Technology

WISA 4 | $9.19 50.66% 33.7% 65M |

Electronic Technology

EDBL | News | $6.73 47.91% 32.39% 13M |

GCTK | $0.715 36.27% 26.62% 640K |

Manufacturing

TCON | $2.33 36.26% 26.61% 2M |

Health Technology

TIRX | $0.48 6.43% 24.58% 4.8M |

KZIA | $0.38 30.58% 23.42% 300K |

Health Technology

VNDA | News | $5.23 29.14% 22.56% 24M |

Health Technology

ATNF | $1.91 29.05% 22.51% 310K |

---

Your saved searches

---